Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia - Seymour, John F; Kipps, Thomas J; Eichhorst, Barbara; Hillmen, Peter; D’Rozario, James; Assouline, Sarit; Owen, Carolyn; Gerecitano, John; Robak, Tadeusz; De la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; et al. (The New England journal of medicine, 2018)
Keywords: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bendamustine Hydrochloride - administration & dosage; Bendamustine Hydrochloride - adverse effects; Bone marrow; Bridged Bicyclo Compounds, Heterocyclic - administration & dosage; Bridged Bicyclo Compounds, Heterocyclic - adverse effects; Cancer therapies; Chemotherapy; Chromosome 17; Chromosome deletion; Chromosomes; Chronic lymphocytic leukemia; Clinical trials; Clonal deletion; Disease-Free Survival; Drug dosages; Drug Resistance, Neoplasm; Evidence-based medicine; Female; Hematology; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Life Sciences; Lymphatic leukemia; Lysis; Male; Middle Aged; Monoclonal antibodies; Neoplasm, Residual; Neutropenia; Neutropenia - chemically induced; Oncology; Patients; Recurrence; Response rates; Rituximab; Rituximab - administration & dosage; Rituximab - adverse effects; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Targeted cancer therapy; Tumor Lysis Syndrome - etiology; Young Adult; Australia; United States--US; California; Recurrence; Lymphocytic; Humans; Middle Aged; Leukemia; Male; Residual; 80 and over; Young Adult; B-Cell; Female; Adult; Tumor Lysis Syndrome; Heterocyclic; Drug Resistance; Neutropenia; Kaplan-Meier Estimate; Rituximab; Antineoplastic Combined Chemotherapy Protocols; Neoplasm; Disease-Free Survival; Chronic; Bendamustine Hydrochloride; Sulfonamides; Aged; Bridged Bicyclo Compounds